HopeStage
Back to all studies
CompletedNCT02153502

AVP-786 Added to Antidepressants for Depression That Has Not Improved Enough

About this titleRead the official source — NCT02153502
Medication studyAges 18+United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Birmingham and 31 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 1, 2014
Recruitment status
Completed
Enrollment listed in the registry
206
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT02153502
Official title
Show the full official title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham · Bellflower · Costa Mesa

26 more locations
  • Garden Grove
  • Lomita
  • Oceanside
  • Riverside
  • Santa Ana
  • Sherman Oaks
  • Denver
  • Bradenton
  • Jacksonville
  • Miami
  • Orange City
  • Orlando
  • Decatur
  • Hoffman Estates
  • Valparaiso
  • Baltimore
  • Glen Burnie
  • Boston
  • Brooklyn
  • New York
  • Staten Island
  • Garfield Heights
  • Oklahoma City
  • Tulsa
  • Philadelphia
  • Murray

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) and Placebo.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies